Answers are grounded in this paper and cite their sources.
High-dose methotrexate (HDMTX) use can be limited by the development of acute kidney injury (AKI). Early AKI detection is paramount to prevent further renal injury and irreversible toxicities. This study sought to determine whether early elimination patterns of MTX would be useful as a biomarker of AKI in HDMTX treatment.
No takes yet. Share an insight, caveat, or question.
Tentoni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: